Lack of information "made us realize that we needed to see data from a third dose from the ongoing trial in order to make a determination," says FDA chief.
In February 2020, the Trump administration drafted a policy document—stamped “not for public distribution or release” and indeed kept from public view for months—that would guide decision makers at every level of government and every sector of the economy in dealing with a new virus that came to be known by the scientific shorthand “Covid-19.”